论文部分内容阅读
摘要目的以PET/CT显像作为参考标准,评价MR/PET显像在肺癌分期中的作用。比较这种新的全身MR/PET显像系统与相应的PET/CT数据两者的定量准确性。材料与方法该研究被伦理委员会批准,并签署相应的知情同意书。10例已明确诊断或临床疑诊为支气管肺癌的病人先行18F-FDGPET/CT显像,紧接着行全身MR/PET显像(用3.0TMRI设备与PET整合而成的新的混合全身显像系统)。MR/PET显像的衰减校正采用脂-水分离技术分段进行。
Abstract Objective To evaluate the role of MR / PET imaging in the staging of lung cancer using PET / CT imaging as a reference standard. The quantitative accuracy of this new whole body MR / PET imaging system with the corresponding PET / CT data was compared. Materials and Methods The study was approved by ethics committee and signed the corresponding informed consent form. Ten patients with definite diagnosis or clinically suspected bronchogenic carcinoma were followed up with 18F-FDG PET / CT imaging followed by whole-body MR / PET imaging (a new hybrid whole-body imaging system with 3.0 TMRI device and PET ). The attenuation correction of MR / PET imaging was performed in stages using the lipid-water separation technique.